These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 9533981)

  • 61. Pharmacokinetic enhancement of protease inhibitor therapy.
    King JR; Wynn H; Brundage R; Acosta EP
    Clin Pharmacokinet; 2004; 43(5):291-310. PubMed ID: 15080763
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Saquinavir soft gelatin capsule: a comparative safety review.
    Gill J; Feinberg J
    Drug Saf; 2001; 24(3):223-32. PubMed ID: 11347724
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapeutic advances: protease inhibitors for the treatment of HIV-1 infection.
    Misson J; Clark W; Kendall MJ
    J Clin Pharm Ther; 1997 Apr; 22(2):109-17. PubMed ID: 9373809
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 2000 Mar; 14(5):626-8. PubMed ID: 10780732
    [No Abstract]   [Full Text] [Related]  

  • 65. Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults.
    von Hentig N; Lötsch J
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3524-7. PubMed ID: 19528289
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Poor penetration of the male genital tract by HIV-1 protease inhibitors.
    Taylor S; Back DJ; Workman J; Drake SM; White DJ; Choudhury B; Cane PA; Beards GM; Halifax K; Pillay D
    AIDS; 1999 May; 13(7):859-60. PubMed ID: 10357387
    [No Abstract]   [Full Text] [Related]  

  • 67. Drug interactions between HIV protease inhibitors and acid-reducing agents.
    Falcon RW; Kakuda TN
    Clin Pharmacokinet; 2008; 47(2):75-89. PubMed ID: 18193914
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Gender: a possible determinant in dosing of dermatologic drugs--an overview.
    Modjtahedi BS; Modjtahedi SP; Maibach HI
    Cutan Ocul Toxicol; 2006; 25(3):195-210. PubMed ID: 16980245
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Delavirdine: clinical pharmacokinetics and drug interactions.
    Tran JQ; Gerber JG; Kerr BM
    Clin Pharmacokinet; 2001; 40(3):207-26. PubMed ID: 11327199
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [HIV protease inhibitors: drug interactions].
    Gérard Y; Maulin L; Dubreuil L; Mouton Y
    Rev Med Interne; 1999 Feb; 20(2):141-50. PubMed ID: 10227092
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
    Kempf DJ; Marsh KC; Kumar G; Rodrigues AD; Denissen JF; McDonald E; Kukulka MJ; Hsu A; Granneman GR; Baroldi PA; Sun E; Pizzuti D; Plattner JJ; Norbeck DW; Leonard JM
    Antimicrob Agents Chemother; 1997 Mar; 41(3):654-60. PubMed ID: 9056009
    [TBL] [Abstract][Full Text] [Related]  

  • 72. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
    Berginc K; Trdan T; Trontelj J; Kristl A
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
    [TBL] [Abstract][Full Text] [Related]  

  • 73. HIV therapy advances. Update on a proteinase inhibitor.
    Vella S
    AIDS; 1994 Sep; 8 Suppl 3():S25-9. PubMed ID: 7840913
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study.
    van Heeswijk RP; Cohen Stuart JW; Burger DM; Beijnen JH; Borleffs JC; Hoetelmans RM;
    Br J Clin Pharmacol; 2002 Feb; 53(2):211-2. PubMed ID: 11851648
    [No Abstract]   [Full Text] [Related]  

  • 75. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies.
    Lin JH
    Adv Drug Deliv Rev; 1997 Sep; 27(2-3):215-233. PubMed ID: 10837559
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.
    Roy U; Chakravarty G; Honer Zu Bentrup K; Mondal D
    Biol Pharm Bull; 2009 Dec; 32(12):2002-9. PubMed ID: 19952419
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir.
    Koks CH; van Heeswijk RP; Veldkamp AI; Meenhorst PL; Mulder JW; van der Meer JT; Beijnen JH; Hoetelmans RM
    AIDS; 2000 Jan; 14(1):89-90. PubMed ID: 10714572
    [No Abstract]   [Full Text] [Related]  

  • 78. Reply: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients.
    Fätkenheuer G; Rockstroh J; Salzberger B
    AIDS; 1998 Jul; 12(11):1402-3. PubMed ID: 9708429
    [No Abstract]   [Full Text] [Related]  

  • 79. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
    Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S
    J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Protease inhibitors: where are they now?
    Gold D; Loftus R
    GMHC Treat Issues; 1995 Jan; 9(1):1-7. PubMed ID: 11367375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.